Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
about
DMH1, a small molecule inhibitor of BMP type i receptors, suppresses growth and invasion of lung cancerMicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistanceMet receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodiaReview of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials.The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapyLarge-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics.EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.Usefulness of endobronchial ultrasound in patients with previously treated thoracic malignancy.Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.Erlotinib resistance in lung cancer: current progress and future perspectives.Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesMechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyTelomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancerKinase dysfunction and kinase inhibitors.Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.The Potential of panHER Inhibition in Cancer.Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.MET: a new promising biomarker in non-small-cell lung carcinoma.Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung CancerLeveraging growth factor induced macropinocytosis for targeted treatment of lung cancer.Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates.Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer.Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathwaySystematic Identification of Oncogenic EGFR Interaction Partners
P2860
Q28511586-2909B763-FA50-409D-94BB-C0D6266A4B90Q28538690-51629520-81F2-41EC-863F-6448A2F33259Q30010161-EF9D0F5C-3522-4DAA-A951-708C3D949DA5Q34180683-F8F90D02-A1EE-4738-8215-5FED86F697B8Q34353920-54F00103-C2F7-4505-8A36-62503ECA2A7CQ34465240-917DA0CC-B170-4016-A399-A0342F54D0CAQ34537725-38DDFD90-7BAE-462B-8A35-DD3041E3536AQ34855692-FAA289A2-D0E2-48A4-9489-3D12924BC27EQ35152542-C1EF0A49-B0C9-4CE0-89C3-A05E017D2042Q35200424-AC17C020-51CB-4F0B-85B1-05468B7C1F73Q35311600-381E07C4-156B-434B-8B67-BBF55D6185EEQ35606916-2A1AC2F8-421B-45F9-8D3C-20A4B245D4F1Q35829430-797FBAB1-0D6E-491D-B86C-2A64E95D97B1Q35872687-0F06F6D0-4F85-4952-9540-F7B9CC057D59Q36168015-3FA24BF4-8B1A-4F87-9557-452E6AC80B1FQ36258125-2F01EC75-5400-4435-82B6-BBC32DD89CF5Q36605522-E0FB070B-FF83-46E7-8495-1F7B1CBA06AFQ36750945-65A6AA0D-A5A3-48D2-B0F5-FEDC6059F1DAQ36850900-23AF5B31-361B-48F5-AF71-06CA3D3D9C8CQ36942619-DCC00E0E-F717-4A41-825A-A2E0BA97C3F9Q37347532-7AA04F22-FD1F-42F9-B777-CDCF456394C5Q37362475-66758794-68DB-4B91-827F-CB478A715A50Q37698720-8C8FDDD0-655D-49A7-A919-A1E1A53724CAQ37701159-22BD8843-8BF9-439E-AB21-0B659B54FB5BQ38075152-5F7547AE-7B55-4192-9DA9-79B9C6E00183Q38168795-26DE8C9B-687E-48AF-BDF6-DE3C540F45E8Q38352587-5C4E6063-A197-41A5-91A0-42F4B99E053BQ38412163-A749ED33-E290-49A6-892D-2F76FFC51AD9Q38427102-C90086F2-2737-47BF-BD32-1776FE9AD13CQ38430194-A749AD4A-AE6B-4BF0-AC02-1659E15DE940Q38594474-5CA1A48B-D672-4D51-85DE-D9B47F4512E9Q38735467-59547EE8-3B94-4139-BB74-E6DB1469D19DQ38823392-7B735D93-92B2-4797-B8F5-79BF3B49D285Q38873867-5C8DA0E6-2E73-43E0-808D-9C87FF186E0FQ38922926-8049074C-B906-478B-835F-2E9EABF9EBFFQ39273308-4A50D779-AA84-4695-8D3B-03ABE27CB8D9Q39311676-96CAF0DF-034C-47F8-89D7-9DE73154A48DQ40705663-BE07F10E-10B6-406E-B96C-2E9011043722Q41623567-4EBB7FEA-BF9E-4208-94FF-3FB446BFB758Q42149620-F2368A88-3C34-40D7-94F4-8A6981E6AA2A
P2860
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mechanisms of resistance to EG ...... in non-small-cell lung cancer.
@en
type
label
Mechanisms of resistance to EG ...... in non-small-cell lung cancer.
@en
prefLabel
Mechanisms of resistance to EG ...... in non-small-cell lung cancer.
@en
P2093
P2860
P921
P356
P1476
Mechanisms of resistance to EG ...... in non-small-cell lung cancer.
@en
P2093
Akira Mogi
Hiroyuki Kuwano
Takayuki Kosaka
P2860
P304
P356
10.1155/2011/165214
P577
2011-06-02T00:00:00Z